Zydus Cadila receives USFDA nod for acetazolamide ER capsules

Zydus Cadila was trading positive post the announcement that the company has bagged a final USFDA approval for Acetazolamide ER Capsules.

 The company is now set to market Acetazolamide extended-release capsules which is an effective carbonic anhydrase inhibitor. It is useful to treat certain types of glaucoma caused by increased ocular pressure and also to prevent mountain sickness. Zydus Cadila will be manufacturing the capsules at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Zydus Cadila is a global pharmaceutical company that focuses on discovery, development, manufacturing and marketing a vast range of healthcare therapies. Zydus Cadila also develops and manufactures a range of diagnostics, herbal products and skin care products.

On Thursday, the stock of Cadila Healthcare opened at Rs. 353.10 per share as against Wednesday’s close of Rs. 352 per share. At 14:00 hours, the shares were trading at Rs. 356.25 per share, up by 1.11 per cent. The stock's intraday high was Rs. 358 and intraday low was at Rs. 353.10 per share on the BSE. Meanwhile, the BSE Sensex was at 36,210.75 level, down by 0.03 per cent.